Top Page
Impedimed Limited
(Sydney:IPD)
Impedimed Limited (IPD) vs. iShares MSCI Australia ETF (EWA)
Impedimed Limited Business Overview & Revenue Model
Impedimed Limited Earnings Call Summary
Impedimed Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.23M | 12.72M | 10.32M | 11.34M | 10.57M | 8.41M |
| Gross Profit | -832.00K | 10.97M | 9.01M | -13.65M | -13.35M | -12.20M |
| EBITDA | -15.69M | -17.55M | -22.05M | -20.49M | -18.65M | -20.70M |
| Net Income | -24.37M | -23.24M | -19.79M | -20.52M | -19.87M | -20.71M |
Balance Sheet | ||||||
| Total Assets | 38.36M | 41.66M | 46.99M | 68.74M | 58.70M | 34.20M |
| Cash, Cash Equivalents and Short-Term Investments | 18.85M | 22.18M | 24.63M | 45.71M | 40.73M | 19.68M |
| Total Debt | 21.93M | 14.49M | 1.14M | 1.45M | 170.00K | 474.00K |
| Total Liabilities | 29.34M | 21.16M | 6.24M | 7.86M | 7.66M | 8.69M |
| Stockholders Equity | 9.02M | 20.50M | 40.74M | 60.88M | 51.04M | 25.51M |
Cash Flow | ||||||
| Free Cash Flow | -8.01M | -15.63M | -20.89M | -24.09M | -20.89M | -15.71M |
| Operating Cash Flow | -17.45M | -14.64M | -17.79M | -18.05M | -15.66M | -13.26M |
| Investing Cash Flow | -873.00K | -989.00K | -3.10M | -6.04M | -5.22M | -2.46M |
| Financing Cash Flow | 21.94M | 13.64M | -481.00K | 27.93M | 39.92M | 16.47M |
Impedimed Limited Technical Analysis
Impedimed Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | AU$42.72M | -6.02 | -44.16% | ― | 25.47% | 14.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$65.92M | 660.00 | -6.35% | ― | 2.23% | -263.16% | |
46 Neutral | AU$34.66M | -1.42 | -74.00% | ― | 23.31% | -17.35% | |
44 Neutral | AU$101.92M | -5.40 | -31.98% | ― | 34.20% | -23.90% | |
44 Neutral | AU$164.04M | -15.03 | -70.55% | ― | ― | -257.32% | |
41 Neutral | AU$54.46M | -4.24 | -128.19% | ― | -14.25% | -22.83% |
Impedimed Limited Corporate Events
ImpediMed Limited has appointed Erik Anderson as a director of the company, effective 25 February 2026, as disclosed in an initial director’s interest notice lodged with the ASX. At the time of his appointment, Anderson holds no direct or indirect interests in ImpediMed securities and has no interests in any related contracts, indicating a starting position free of equity ties or contractual entanglements that could affect governance and alignment with existing shareholders.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has appointed U.S. medtech veteran Erik Anderson as an independent non-executive director, adding deep commercial experience from his tenure leading major business units at Hologic, including Breast & Skeletal Health and Cynosure. Anderson’s background in breast health, body composition and medical aesthetics closely aligns with ImpediMed’s priorities in breast cancer-related lymphoedema, heart health and body composition, strengthening the company’s U.S. commercial capabilities.
The board sees his appointment as reinforcing ImpediMed’s strategic focus on the growing cancer survivorship sector and the expansion of its SOZO digital platform across oncology and broader chronic care. With guidelines continuing to endorse bioimpedance spectroscopy for early lymphoedema detection and ImpediMed uniquely offering FDA-cleared BIS-based lymphoedema assessment, the new board addition is expected to support the company’s efforts to capitalise on a large U.S. market opportunity and drive SaaS subscription growth.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed director Christine Emmanuel-Donnelly has increased her indirect stake in the company through an on-market purchase executed via the Donnelly Superannuation Fund. The fund acquired 1.5 million ImpediMed ordinary shares at $0.019573 per share, lifting its holding to 3,236,255 shares, while her direct and other indirect holdings through IDEAHL Pty Ltd remain unchanged, modestly strengthening insider ownership in the stock.
The transaction signals continued financial commitment from a board member and may be interpreted by investors as a sign of confidence in ImpediMed’s outlook and valuation. With no shares disposed and all changes limited to an on-market trade, the move marginally consolidates Emmanuel-Donnelly’s overall economic interest in the company without altering its broader capital structure.
The most recent analyst rating on (AU:IPD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has released an investor presentation outlining its Q2 FY26 results, which will be delivered to investors and analysts, signalling ongoing engagement with the market about its financial and operational performance. While specific figures are not disclosed in the release, the scheduled presentation underscores the company’s efforts to maintain transparency with stakeholders and could shape investor perceptions of its near-term outlook and strategic progress.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed reported record Q2 FY26 revenue of $3.9 million, ARR of $14.4 million, and $18.9 million in cash, while expanding SOZO unit sales and achieving near-national lymphoedema reimbursement, supporting commercial pilots in heart health and launches in wellness and weight management with a strong U.S. pipeline. Management emphasized the SOZO Pro rollout, strategic conference presence, and discussions with partners to accelerate growth across BCRL, heart failure, and weight-loss indications, suggesting improving operating momentum despite ongoing cash outflows.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed will release its Appendix 4C quarterly cash flow report for the period ending 31 December 2025 on 29 January 2026 and will host an investor webinar the same day, led by CEO and Managing Director Dr Parmjot Bains and CFO and Executive Director McGregor Grant. The session, which requires pre‑registration via the company’s investor hub, will feature a management presentation followed by a live Q&A, signalling an ongoing effort to maintain transparent engagement with shareholders around the company’s financial performance and outlook.
The most recent analyst rating on (AU:IPD) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited has lodged an updated Appendix 2A application with the ASX seeking quotation of new securities under its issuer code IPD. The filing, dated 16 January 2026, corrects information in Part 5 of a previous Appendix 2A submitted the same day, signalling an administrative clarification rather than a change in capital-raising strategy or operational outlook for investors and other stakeholders.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has disclosed a change in the holdings of director Andrew Grant, who received 100,563 new ordinary shares, increasing his direct interest to 2,973,309 shares. The shares were issued on 14 January 2026 in lieu of 15% of his director fees for the quarter ended 31 December 2025, indicating the company’s continued use of equity-based remuneration to align director incentives with shareholder interests; no trades occurred during a closed period, and there were no changes to any director-related contracts.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has disclosed a change in the securities held by director Ms Christine Emmanuel-Donnelly, reflecting an issuance of 146,408 ordinary shares to IDEAHL Pty Ltd, a trustee entity for the Donnelly Family Trust, in lieu of 15% of her director fees for the quarter ended 31 December 2025, at a deemed price of $0.0355 per share. Following this transaction, Emmanuel-Donnelly’s overall holding, including direct interests and those via the Donnelly Superannuation Fund and IDEAHL Pty Ltd, has increased, underscoring the company’s practice of partially remunerating directors in equity and modestly aligning board compensation with shareholder interests without cash outlay, though the change does not alter control or signal any broader strategic shift.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has disclosed a change in the interests of director Janelle Delaney, who increased her direct holding in the company by 100,563 ordinary shares on 14 January 2026. The additional shares were issued at $0.0355 per share in lieu of 15% of her director fees for the quarter ended 31 December 2025, leaving her with 1,982,044 shares held directly and 2,921,387 shares held indirectly through the Delaney Family Superannuation Fund, signaling continued alignment of director compensation with shareholder equity.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has disclosed a change in the shareholding of director Fiona Bones, who received 100,563 ordinary shares on 14 January 2026, increasing her holding to 1,973,309 shares. The new shares were issued in lieu of 15% of her director fees for the quarter ended 31 December 2025, signalling continued alignment of board compensation with equity ownership, though the company reported no related changes in director interests in contracts or any trading during a closed period.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited has applied to the ASX for quotation of 448,097 ordinary fully paid shares issued to its non-executive directors under the company’s Non-Executive Director Share Plan, representing 15% of director fees for the quarter ended 31 December 2025. The move reflects the company’s ongoing practice of aligning board remuneration with shareholder interests by partially paying director fees in equity, modestly increasing the company’s quoted share capital and reinforcing governance incentives for its non-executive directors.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited has notified the ASX that certain equity instruments on issue have lapsed, including 4,742,000 options with various expiry dates and prices, and 108,079 performance rights, all of which ceased on 31 December 2025 after the conditions attached to them were not met or became incapable of being satisfied. The cancellation of these conditional rights modestly reduces the company’s potential future share dilution, clarifies its capital structure for investors, and may reflect performance or milestone criteria that were not achieved under existing incentive arrangements.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
Impedimed Limited has applied to the ASX for quotation of 870,255 new fully paid ordinary shares, which were issued to an executive as part of their base remuneration for the quarter ended 31 December 2025 under the company’s Executive Share Plan. The move modestly increases the company’s share count and reflects Impedimed’s continued use of equity-based compensation to remunerate senior management, aligning executive interests with shareholders while managing cash outflows.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
ImpediMed Limited has announced that additional U.S. insurers have initiated coverage for the use of bioimpedance spectroscopy (BIS) for lymphoedema assessment, expanding reimbursement to over 314 million covered lives. This development marks a significant milestone in providing broader access to early detection and monitoring of lymphoedema, enhancing patient care and potentially reducing long-term complications. The expanded insurance coverage is expected to boost the commercial viability of ImpediMed’s SOZO platform, facilitating its adoption and supporting the company’s mission to improve health outcomes for cancer patients at risk of lymphoedema.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.